BR112021022421A2 - Ensaio multiplex para determinar a razão de ss-amiloide 42/40 em espécimes de plasma humano - Google Patents
Ensaio multiplex para determinar a razão de ss-amiloide 42/40 em espécimes de plasma humanoInfo
- Publication number
- BR112021022421A2 BR112021022421A2 BR112021022421A BR112021022421A BR112021022421A2 BR 112021022421 A2 BR112021022421 A2 BR 112021022421A2 BR 112021022421 A BR112021022421 A BR 112021022421A BR 112021022421 A BR112021022421 A BR 112021022421A BR 112021022421 A2 BR112021022421 A2 BR 112021022421A2
- Authority
- BR
- Brazil
- Prior art keywords
- amyloid
- ratio
- human plasma
- plasma specimens
- multiplex assay
- Prior art date
Links
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 title abstract 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 title abstract 2
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 title abstract 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title abstract 2
- 238000007837 multiplex assay Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000002731 protein assay Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/34—Purifying; Cleaning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
ensaio multiplex para determinar a razão de ß-amiloide 42/40 em espécimes de plasma humano. a presente tecnologia se refere a métodos para diagnosticar, monitorar a progressão de, avaliar a eficácia de tratamento de ou avaliar risco para desenvolvimento de um distúrbio neurodegenerativo em um paciente. esses métodos se baseiam em determinar a razão entre ß-amiloide 42 (aß42) e ß-amiloide 40 (aß40) em uma amostra de fluido corporal coletada de um paciente que tem ou é suspeito de ter um distúrbio neurodegenerativo, utilizando um ensaio de proteína multiplex aperfeiçoado e altamente sensível que detecta simultaneamente aß42 e aß40.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962846565P | 2019-05-10 | 2019-05-10 | |
| PCT/US2020/032010 WO2020231774A1 (en) | 2019-05-10 | 2020-05-08 | MULTIPLEX ASSAY FOR DETERMINING THE ß-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022421A2 true BR112021022421A2 (pt) | 2021-12-28 |
Family
ID=73289510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022421A BR112021022421A2 (pt) | 2019-05-10 | 2020-05-08 | Ensaio multiplex para determinar a razão de ss-amiloide 42/40 em espécimes de plasma humano |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220260592A1 (pt) |
| EP (1) | EP3966572A4 (pt) |
| CN (1) | CN114072678A (pt) |
| BR (1) | BR112021022421A2 (pt) |
| CA (1) | CA3139530A1 (pt) |
| MX (1) | MX2021013715A (pt) |
| WO (1) | WO2020231774A1 (pt) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ516848A (en) * | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
| WO2011033046A1 (en) * | 2009-09-18 | 2011-03-24 | Probiodrug Ag | Novel assay for the detection of amyloid beta peptides |
| AR079443A1 (es) * | 2009-12-11 | 2012-01-25 | Araclon Biotech Sl | Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides |
| WO2012142300A2 (en) * | 2011-04-12 | 2012-10-18 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event |
| EP2511296A1 (en) * | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| WO2016115256A1 (en) * | 2015-01-13 | 2016-07-21 | Quanterix Corporation | Methods relating to improving accuracy of capture object-based assays |
-
2020
- 2020-05-08 CN CN202080049343.0A patent/CN114072678A/zh active Pending
- 2020-05-08 MX MX2021013715A patent/MX2021013715A/es unknown
- 2020-05-08 US US17/610,044 patent/US20220260592A1/en active Pending
- 2020-05-08 WO PCT/US2020/032010 patent/WO2020231774A1/en unknown
- 2020-05-08 EP EP20805855.2A patent/EP3966572A4/en active Pending
- 2020-05-08 BR BR112021022421A patent/BR112021022421A2/pt unknown
- 2020-05-08 CA CA3139530A patent/CA3139530A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020231774A1 (en) | 2020-11-19 |
| CN114072678A (zh) | 2022-02-18 |
| MX2021013715A (es) | 2022-01-24 |
| EP3966572A4 (en) | 2023-01-25 |
| EP3966572A1 (en) | 2022-03-16 |
| CA3139530A1 (en) | 2020-11-19 |
| US20220260592A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017021305A2 (pt) | dispositivo de teste de fluxo lateral, e, método e kit para detecção quantitativa de um analito em uma amostra de saliva | |
| BR112019011959A8 (pt) | Aparelho e método de monitoramento de gravidez ou trabalho de parto | |
| BR112013033488B8 (pt) | Métodos para facilitar o diagnóstico do comprometimento cognitivo devido a doença de alzheimer ou comprometimento cognitivo leve (mci)e kit | |
| ATE456055T1 (de) | Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden | |
| BR112014010718A2 (pt) | métodos e sistemas para detecção de analito em amostra | |
| WO2015070037A3 (en) | Polynucleotide conjugates and methods for analyte detection | |
| BR112015019259A2 (pt) | coleta de dados de saúde pessoal | |
| NZ594772A (en) | Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c | |
| JP2011510309A5 (pt) | ||
| JP2016118568A5 (pt) | ||
| PH12020551371A1 (en) | Assays to detect neurodegeneration | |
| ATE550658T1 (de) | Verfahren für den nachweis oder die diagnose neurodegenerativer erkrankungen oder leiden | |
| JP2017504011A5 (pt) | ||
| MX2021012347A (es) | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. | |
| BR112015008042A2 (pt) | diagnósticos complementares para terapia com inibidor de quinase da família tec | |
| BR112017022320A2 (pt) | métodos para tratamento de câncer de pulmão | |
| WO2007015113A3 (en) | New protein isoforms of the pif-family and uses thereof | |
| EP3788167A4 (en) | METHODS OF DIAGNOSIS AND TREATMENT OF PATIENTS WITH CUTANEOUS SKATOPHONE CARCINOMA | |
| FR2900936B1 (fr) | Procede et methodes de detection de la maladie d'alzheimer | |
| BR112019001384A2 (pt) | teste de combinação para câncer colorretal | |
| AR048031A1 (es) | Metodos para estimar la necesidad y efectividad de la terapia con antioxidantes | |
| MX2022011632A (es) | Anticuerpos contra mucina 17 y usos de los mismos. | |
| MX2021007951A (es) | Ensayo multiplexado y metodos de uso del mismo. | |
| BR112021022421A2 (pt) | Ensaio multiplex para determinar a razão de ss-amiloide 42/40 em espécimes de plasma humano | |
| BR112015021507A8 (pt) | métodos e composições para o diagnóstico de pré-eclampsia em uma mulher grávida e kit de ensaio de diagnóstico |